{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Losulazine (U-54,669F) is an antihypertensive agent acting by a sympatholytic mechanism. It appears to alter peripheral sympathetic neurogenic function but apparently does not enter the central nervous system. Losulazine effectively lowered the blood pressure in patients with hypertension.
Status:
Investigational
Source:
NCT04316546: Phase 2 Interventional Recruiting Proteus Syndrome
(2022)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Miransertib (ARQ 092) is a selective, pan-AKT (protein kinase B) inhibitor that potently inhibits AKT1, 2 and 3 isoforms. Miransertib binds inactive AKT, preventing membrane localization and subsequent AKT activation, and binds active AKT, resulting in direct inhibition. Miransertib participates in Phase 1/2 of clinical trials to treat patients at least 2 years of age with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS). In addition, the drug is involved in the phase I trial in patients with lymphoma, endometrial cancer, and AKT1 E17K mutations. Recently was shown that miransertib could be an excellent lead compound for the development of new oral drug therapy for visceral and cutaneous leishmaniasis.
Status:
Investigational
Source:
NCT01332266: Phase 1/Phase 2 Interventional Completed Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Golvatinib is a highly potent, small-molecule, ATP-competitive inhibitor of c-Met and multiple members of the Eph receptor family plus c-Kit and Ron. Eisai was developing an oral formulation of golvatinib, which acts as both a c-Met inhibitor and a vascular endothelial growth factor receptor 2 antagonist with potential antineoplastic activity. Golvatinib binds to and inhibits the activities of both c-Met and VEGFR-2, which may inhibit tumor cell growth and survival of tumor cells that overexpress these receptor tyrosine kinases. c-Met and VEGFR-2 are upregulated in a variety of various tumor cell types and play important roles in tumor cell growth, migration and angiogenesis. Clinical trials involving several forms of cancer are currently underway.
Status:
Investigational
Source:
NCT02389790: Phase 2 Interventional Completed Crohn's Disease
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Amiselimod (MT-1303) is a selective sphingosine 1-phosphate 1 (S1P1 ) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical, phase I and II studies. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.
Status:
Investigational
Source:
NCT00808977: Phase 2 Interventional Completed Ulcerative Colitis
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Dersalazine is a locally-acting compound. It is a potent platelet activating factor (PAF)-antagonist. Dersalazine inhibited IL-1beta or TNF-alpha production in THP-1 or U937 cells, respectively. Dersalazine sodium reduced colonic proinflammatory cytokines IL-1b, IL-6, and IL-17 in dextran sodium sulphate (DSS)–induced colitis. After oral administration, dersalazine sodium is mostly unabsorbed until it reaches the large bowel where the azo bond is reduced by bacteria releasing the active compound. Dersalazine had been in phase I clinical trial for the treatment of ulcerative colitis. No serious adverse reactions were detected in clinical trial. However, no recent development has been reported.
Status:
Investigational
Source:
NCT00551811: Phase 1 Interventional Completed Pulmonary Disease, Chronic Obstructive
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Elubrixin (SB-656933) is a CXCR2 antagonist that demonstrates dose-dependent effects on neutrophil activation and recruitment. In preclinical studies, the compound was shown to inhibit CXCL1-induced CD11b up-regulation on PMNs in an in vitro whole blood assay and to be active in in vivo rodent inhalation challenge models of airway inflammation that used endotoxin and ozone to induce airway neutrophilia. Elubrixin was being developed by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease, cystic fibrosis and ulcerative colitis. Elubrixin was withdrawn from the Phase II trial due to the lack of efficacy.
Status:
Investigational
Source:
NCT01954238: Phase 1 Interventional Completed Healthy Volunteers
(2013)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02389790: Phase 2 Interventional Completed Crohn's Disease
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Amiselimod (MT-1303) is a selective sphingosine 1-phosphate 1 (S1P1 ) receptor modulator which is currently being developed for the treatment of various autoimmune diseases. Unlike some other S1P receptor modulators, amiselimod seemed to show a favourable cardiac safety profile in preclinical, phase I and II studies. Amiselimod may be potentially useful for treatment of multiple sclerosis; inflammatory diseases; autoimmune diseases; psoriasis and inflammatory bowel diseases. Amiselimod is currently being developed by Mitsubishi Tanabe Pharma Corporation.
Status:
Investigational
Source:
NCT00599911: Phase 2 Interventional Completed Major Depressive Disorder
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tedatioxetine (previously known as Lu AA24530) is a multimodal antidepressant that was developed for the treatment of depression and anxiety disorders (generalized anxiety disorder mainly). Tedatioxetine is a monoamine enhancer with reuptake inhibition at monoamine transporters and possesses an antagonist activity at 5-HT3 and 5-HT2c receptors. In 2009, the drug was studied in phase II clinical trials where it showed positive results in major depressive disorder. However, it remains unclear as to whether tedatioxetine development has been postponed and/or abandoned.
